VKTX

Viking Therapeutics Inc

VKTX.US vikingtherapeutics.com
32.13
-0.57 (-1.74%)
USD · NASDAQ
52-week range
22.96
43.15
Trading at 45% of the 52-week range
Market Cap
3.81B
P/E Ratio
0.00
Forward P/E
0.00
Book Value
3.50
Div. Yield
N/A
% Institutions
66.12%
% Insiders
3.10%

1 Year

+24.2%

3 Year

+103.6%

10 Year

+2,352.7%
Description

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Company Information

Company Name
Viking Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US92686J1060
CIK: 0001607678
CUSIP: 92686J106
Currency: USD
Full Time Employees: 65
Phone: 858 704 4660
Fiscal Year End: December
IPO Date: Apr 29, 2015
Description:

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Address:

9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121

People

Directors & Officers

Name Title Year Born
Dr. Brian Lian Ph.D. President, CEO & Director 1966
Mr. Gregory S. Zante CPA Chief Financial Officer 1971
Mr. Michael Morneau Vice President of Finance & Administration 1965
Ms. Katherine Mercier Vice President of Quality & Compliance NA
Mr. Kenneth J. Herman M.B.A. Senior Vice President of Commercial, Marketing & Sales NA
Dr. Geoffrey E. Barker Ph.D. Chief Development Officer NA
Mr. Neil Aubuchon B.A., M.B.A. Chief Commercial Officer 1970
Dr. Nils U. Olsson Ph.D. Senior Vice President of Technical Operations NA
Dr. Hubert C. Chen M.D., M.P.H. Chief Medical Officer 1969

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 10, 2026 Neil William Aubuchon N/A Purchase 4.48K $33.50 $149.91K
Jan 05, 2026 Brian Lian N/A Sale 233.41K $32.96 $7.69M
Jan 05, 2026 Greg Zante N/A Sale 57.66K $32.90 $1.90M
Jan 05, 2026 Marianna Mancini N/A Sale 57.66K $32.98 $1.90M
Jan 02, 2026 Matthew W Foehr N/A Sale 16.00K $35.11 $561.76K
Oct 28, 2025 Brian Lian N/A Sale 38.99K $35.01 $1.37M
Oct 28, 2025 Greg Zante N/A Sale 6.19K $35.00 $216.48K
Oct 28, 2025 Marianna Mancini N/A Sale 6.19K $35.00 $216.48K
Oct 27, 2025 Charles A Rowland Jr N/A Sale 60.00K $35.57 $2.13M
Jul 03, 2025 Brian Lian N/A Sale 26.89K $27.80 $747.51K
Jul 03, 2025 Greg Zante N/A Sale 4.27K $27.76 $118.42K
Jul 03, 2025 Marianna Mancini N/A Sale 4.27K $27.77 $118.47K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 6.88M Mar 31, 2026 5.90% $0.00 4.06%
FMR Inc 6.02M Mar 31, 2026 5.16% $0.01 -8.13%
Vanguard Capital Management, LLC 5.01M Mar 31, 2026 4.30% $0.00 0.00%
Vanguard Portfolio Management, LLC 4.46M Mar 31, 2026 3.83% $0.01 0.00%
Two Sigma Investments LLC 4.43M Mar 31, 2026 3.80% $0.12 81.96%
State Street Corp 4.40M Mar 31, 2026 3.77% $0.00 -1.12%
Morgan Stanley - Brokerage Accounts 3.01M Mar 31, 2026 2.58% $0.01 -2.03%
Geode Capital Management, LLC 2.08M Mar 31, 2026 1.78% $0.00 4.39%
American Century Companies Inc 1.82M Jun 30, 2026 1.56% $0.03 -12.63%
Ameriprise Financial Inc 1.68M Mar 31, 2026 1.44% $0.01 25.36%
D. E. Shaw & Co LP 1.61M Jun 30, 2026 1.38% $0.03 -4.22%
UBS Group AG 1.35M Mar 31, 2026 1.16% $0.01 44.13%
Citadel Advisors Llc 1.26M Mar 31, 2026 1.08% $0.01 -27.14%
The Goldman Sachs Group Inc 960.57K Mar 31, 2026 0.82% $0.00 15.36%
Vestal Point Capital LP 914.15K Mar 31, 2026 0.78% $0.83 0.00%
Jane Street Group LLC 748.95K Mar 31, 2026 0.64% $0.00 -50.11%
Charles Schwab Investment Management Inc 736.47K Mar 31, 2026 0.63% $0.00 5.17%
Vanguard Fiduciary Trust Co 710.41K Mar 31, 2026 0.61% $0.01 0.00%
Susquehanna International Group, LLP 705.81K Mar 31, 2026 0.61% $0.00 -50.43%
Pictet Asset Manangement SA 682.91K Jun 30, 2026 0.59% $0.03 -1.92%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 State Street® SPDR® S&P® Biotech ETF 3.78M 3.24% ▼ 1.06% Aug 31, 2026
2 Vanguard MStar Total Stk Mkt Idx Invest 3.51M 3.01% ▲ 0.40% Jul 31, 2026
3 Vanguard Small Cap Index 2.54M 2.17% ▲ 0.23% Jul 31, 2026
4 Vanguard MStar Small Cap Growth Indx Inv 1.47M 1.26% ▲ 0.29% Jul 31, 2026
5 Vanguard Institutional Extnd Mkt Idx Tr 1.34M 1.15% ▲ 0.54% Jul 31, 2026
6 American Century Heritage Inv 1.33M 1.14% ▼ 15.15% Jun 30, 2026
7 American Century US Opport. Mid Cap Gr 1.33M 1.14% ▼ 15.15% Jun 30, 2026
8 Jupiter Merian Glb Eq Abs Rt I USD Acc 1.30M 1.11% ▲ 0.00% Dec 31, 2025
9 Fidelity Advisor Growth Opps M 1.06M 0.91% ▲ 0.00% Jul 31, 2026
10 CT (Lux) American Smaller Com 9U USD 957.61K 0.82% ▲ 2.40% Jul 31, 2026

Financial Highlights

Market Cap: $3.81B
PEG Ratio: $-0.03
Book Value: $3.50
Earnings/Share: $-4.54
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -51.86%
ROE (TTM): -88.85%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $3.43B
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 116.65M
Shares Float: 113.73M
% Insiders: 3.10%
% Institutions: 66.12%
Short % Float: 20.19%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-431.00K
Gross Profit
subtotal
$-431.00K
SG&A
adjust
$-48.39M
R&D
adjust
$-344.96M
Operating Income
subtotal
$-393.34M
Other / Non-Operating Items
adjust
$33.70M
Net Income
subtotal
$-359.64M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about VKTX.US!